AC Immune SA (ACIU)

AC Immune is a Swiss biopharmaceutical company focused on immunotherapy for neurodegenerative diseases. The company develops vaccines and monoclonal antibodies designed to trigger immune responses against toxic protein aggregates implicated in Alzheimer’s disease, Parkinson’s disease, and other neurological conditions. Its scientific approach centers on activating the body’s immune system to clear misfolded tau, alpha-synuclein, and other pathological proteins.

Platform and Development Stage

AC Immune operates proprietary immunotherapy platforms that generate both active vaccines and passive antibody therapies. The company’s candidates remain in clinical development; none have received regulatory approval. The pipeline includes programs targeting tau pathology, synucleinopathy, and associated neuroinflammation. As a clinical-stage biotech, AC Immune depends on partnerships with larger pharmaceutical companies, capital raises, and milestone payments to fund ongoing trials and operations.

Industry Position and Partnerships

The company competes in the crowded Alzheimer’s and neurodegeneration therapeutic space, where multiple mechanisms and approaches vie for clinical and commercial success. AC Immune differentiates through its focus on immune-mediated protein clearance, though it faces competition from both established pharma companies and other biotech firms pursuing tau-targeting, amyloid-focused, and neuroinflammation strategies. Strategic collaborations with pharmaceutical partners help distribute development risk and provide funding for late-stage trials.

At a glance

Stage: Clinical development (Phase 2 and earlier trials)
Key programs: Tau-targeting vaccines, synuclein-targeting therapies, neuroinflammation candidates
Revenue model: Partnership milestones, royalties on partnered drugs; currently pre-commercial
Listing: NASDAQ-listed, ticker ACIU
Geography: Swiss headquarters; development partnerships global
Sector: Biopharmaceutical / neurology
Key metric to track: Clinical trial progression, partnership announcements, cash runway